{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:55:18Z","timestamp":1790765718419,"version":"4.1.0"},"reference-count":19,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Diffuse large B-cell lymphoma (DLBCL) is an aggressive hematologic malignancy with a defined, first-line (1L) standard of care (SOC). Several novel agents have been approved for the treatment of relapsed\/refractory (R\/R) disease in recent years, leading to a heterogeneous treatment landscape in later lines of therapy (LOTs). Our study aimed to characterize real-world treatment patterns for patients who received third-line or later (3L+) therapy using a multiple index date qualification methodology to enable a comparison to clinical trials. Methods: This observational, retrospective study identified eligible patients in the COTA (now Verana Health) electronic health record-based, DLBCL dataset. Patients were assessed for eligibility at the initiation of each 3L+ LOT. The results were summarized overall and by qualification methodology, and the Kaplan\u2013Meier method was used to evaluate real-world overall survival (rwOS). Results: Among 476 unique patients, 716 index-LOTs were identified, and 3L+ index therapies were variable. The Eastern Cooperative Oncology Group (ECOG) score was 0\u20132 for 57% of qualifying-LOTs and missing\/unknown (M\/U) for 43%. The median rwOS among all-qualifying, first-qualifying, and last-qualifying index-LOTs was 8.0 (95% CI: 6.9, 10.6), 11.4 (95% CI: 9.7, 13.6), and 6.3 months (95% CI: 5.3, 8.0), respectively. Patients with M\/U ECOG did not experience worse outcomes compared to those with ECOG 0\u20132. Conclusions: The outcomes in our study are similar to those from comparator arms of contemporary clinical trials, demonstrating a continued unmet need for effective, SOC therapy for patients with 3L+ DLBCL. Additionally, the variable outcomes based on qualifying index-LOTs underscores the criticality of appropriate patient identification and comparison for clinical trials.<\/jats:p>","DOI":"10.3390\/jcm15197596","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:25:42Z","timestamp":1790760342000},"page":"7596","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Treatment Patterns and Outcomes Among Patients with Third-Line or Later (3L+) Diffuse Large B-Cell Lymphoma (DLBCL) with Multiple Qualifying Index Dates Treated in the United States"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0816-040X","authenticated-orcid":false,"given":"Michael","family":"Wallington","sequence":"first","affiliation":[{"name":"Pfizer, Ltd., Walton Oaks, Tadworth KT20 7NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Fei","family":"Jie","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Bothell, WA 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Monica","family":"Patterson","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Bothell, WA 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Repetny","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Bothell, WA 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[{"name":"Pfizer, Inc., Bothell, WA 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Simon","family":"Purcell","sequence":"additional","affiliation":[{"name":"Pfizer, Ltd., Walton Oaks, Tadworth KT20 7NS, UK"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Jacob","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Verana Health (Formerly COTA, Inc.), New York, NY 10014, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7516-593X","authenticated-orcid":false,"given":"Christina M.","family":"Zettler","sequence":"additional","affiliation":[{"name":"Verana Health (Formerly COTA, Inc.), New York, NY 10014, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Andrew J.","family":"Belli","sequence":"additional","affiliation":[{"name":"Verana Health (Formerly COTA, Inc.), New York, NY 10014, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Laura L.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Verana Health (Formerly COTA, Inc.), New York, NY 10014, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Ching-Kun","family":"Wang","sequence":"additional","affiliation":[{"name":"Verana Health (Formerly COTA, Inc.), New York, NY 10014, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2024-197938","article-title":"Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes","volume":"144","author":"Salles","year":"2024","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management","volume":"96","author":"Barta","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_5","unstructured":"National Comprehensive Cancer Network (2026). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): B-Cell Lymphomas, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_8","unstructured":"(2026, September 11). SEER Cancer Stat Facts: Diffuse Large B-Cell Lymphoma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2217\/fon-2023-0385","article-title":"Treatment Patterns and Costs Among US Patients with Diffuse Large B-Cell Lymphoma not Treated with 2L Stem Cell Transplantation","volume":"20","author":"Acheampong","year":"2024","journal-title":"Future Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e7173","DOI":"10.1002\/cam4.7173","article-title":"Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy","volume":"13","author":"Sineshaw","year":"2024","journal-title":"Cancer Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41408-025-01412-8","article-title":"Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database","volume":"16","author":"Shadman","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1080\/10428194.2024.2371472","article-title":"Real-world outcomes with novel therapies in relapsed\/refractory diffuse large B-cell lymphoma","volume":"65","author":"Crombie","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1158\/1078-0432.CCR-24-1729","article-title":"FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas","volume":"30","author":"Kasamon","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3324\/haematol.2023.284056","article-title":"More than a lonca-shot: Beating the odds in relapsed\/refractory diffuse large B-cell lymphoma","volume":"109","author":"Ho","year":"2024","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available","volume":"183","author":"Robins","year":"2016","journal-title":"Am. J. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pst.2107","article-title":"How to choose a time zero for patients in external control arms","volume":"20","author":"Backenroth","year":"2021","journal-title":"Pharm. Stat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0272989X221096070","article-title":"Approaches to Selecting \u201cTime Zero\u201d in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches","volume":"42","author":"Hatswell","year":"2022","journal-title":"Med. Decis. Mak."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/CCI.20.00125","article-title":"Comparisons of Real-World Time-to-Event End Points in Oncology Research","volume":"5","author":"Walker","year":"2021","journal-title":"JCO Clin. Cancer Inform."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7596\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:56:26Z","timestamp":1790762186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":19,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197596"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197596","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]}}}